The Biology Behind mTOR Inhibition in Sarcoma

The Biology Behind mTOR Inhibition in Sarcoma Xiaolin Wan, Lee J. Helman Oncologist 2007; 12: 1007-1018 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in sarcomas and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (required). Learning Objectives After completing this course, the reader should be able to: Discuss the function of the mTOR pathway in cancer cell growth and survival. Describe the potential mechanism of targeting this pathway by rapamycin and its derivatives for cancer therapy. Summarize the clinical trials performed with mTOR inhibitors in the treatment of sarcomas and suggest the future clinical development of these inhibitors in the treatment of sarcomas. The NIH/FAES designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: August 31, 2007 Most Recent Review: August 31, 2007* Most Recent Update: August 31, 2007 Date Credit Expires: August 31, 2009 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

• Take this course